{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T21:47:45Z","timestamp":1773784065332,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40744-025-00813-2","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:39:09Z","timestamp":1767775149000},"page":"403-421","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantifying Disease Activity Despite Treatment with Tumor Necrosis Factor Inhibitors Among Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Real-World Results from the PPD CorEvitas Psoriatic Arthritis\/Spondyloarthritis Registry"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip","family":"Mease","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0396-2646","authenticated-orcid":false,"given":"Christopher D.","family":"Saffore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhumik","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Ciecinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Blachley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Eliot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Middaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"issue":"1","key":"813_CR1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","volume":"17","author":"LC Coates","year":"2017","unstructured":"Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017;17(1):65\u201370.","journal-title":"Clin Med (Lond)"},{"issue":"4","key":"813_CR2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545\u201368.","journal-title":"Rheum Dis Clin North Am"},{"issue":"12","key":"813_CR3","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","volume":"80","author":"V Navarro-Comp\u00e1n","year":"2021","unstructured":"Navarro-Comp\u00e1n V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis. 2021;80(12):1511\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"813_CR4","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001108","volume":"5","author":"C L\u00f3pez-Medina","year":"2019","unstructured":"L\u00f3pez-Medina C, Ramiro S, van der Heijde D, et al. Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis. RMD Open. 2019;5(2):e001108.","journal-title":"RMD Open"},{"issue":"6","key":"813_CR5","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s40744-023-00602-9","volume":"10","author":"N Frede","year":"2023","unstructured":"Frede N, Hiestand S, Schauer F, et al. Psoriasis and psoriatic arthritis have a major impact on quality of life and depressive symptoms: a cross-sectional study of 300 patients. Rheumatol Ther. 2023;10(6):1655\u201368.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"813_CR6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12955-020-01422-z","volume":"18","author":"LC Coates","year":"2020","unstructured":"Coates LC, Orbai AM, Azevedo VF, et al. Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire. Health Qual Life Outcomes. 2020;18(1):173.","journal-title":"Health Qual Life Outcomes"},{"key":"813_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001223","author":"G Haugeberg","year":"2020","unstructured":"Haugeberg G, Michelsen B, Kavanaugh A. Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: a cross-sectional study of outpatient clinic patients in the biologic treatment era. RMD Open. 2020. https:\/\/doi.org\/10.1136\/rmdopen-2020-001223.","journal-title":"RMD Open"},{"issue":"11","key":"813_CR8","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3899\/jrheum.171406","volume":"45","author":"K Wervers","year":"2018","unstructured":"Wervers K, Luime JJ, Tchetverikov I, et al. Influence of disease manifestations on health-related quality of life in early psoriatic arthritis. J Rheumatol. 2018;45(11):1526\u201331.","journal-title":"J Rheumatol"},{"issue":"11","key":"813_CR9","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/acr.23249","volume":"69","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Karki C, Palmer JB, et al. Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry. Arthritis Care Res Hoboken. 2017;69(11):1692\u20139.","journal-title":"Arthritis Care Res Hoboken"},{"issue":"1","key":"813_CR10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","volume":"3","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Rheumatol Ther. 2016;3(1):91\u2013102.","journal-title":"Rheumatol Ther"},{"key":"813_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002663","author":"U Kiltz","year":"2023","unstructured":"Kiltz U, Hoeper K, Hammel L, et al. Work participation in patients with axial spondyloarthritis: high prevalence of negative workplace experiences and long-term work impairment. RMD Open. 2023. https:\/\/doi.org\/10.1136\/rmdopen-2022-002663.","journal-title":"RMD Open"},{"issue":"12","key":"813_CR12","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/acr.24426","volume":"73","author":"M Garrido-Cumbrera","year":"2021","unstructured":"Garrido-Cumbrera M, Bundy C, Navarro-Comp\u00e1n V, et al. Patient-reported impact of axial spondyloarthritis on working life: results from the European map of axial spondyloarthritis survey. Arthritis Care Res Hoboken. 2021;73(12):1826\u201333.","journal-title":"Arthritis Care Res Hoboken"},{"issue":"5","key":"813_CR13","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.semarthrit.2014.10.009","volume":"44","author":"A Boonen","year":"2015","unstructured":"Boonen A, Sieper J, van der Heijde D, et al. The burden of non-radiographic axial spondyloarthritis. Semin Arthritis Rheum. 2015;44(5):556\u201362.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"813_CR14","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136\u201346.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"813_CR15","volume":"4","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Deodhar A, FitzGerald O, et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open. 2018;4(1):e000582.","journal-title":"RMD Open"},{"issue":"9","key":"813_CR16","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1136\/annrheumdis-2013-204902","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014;73(9):1689\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"813_CR17","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/ard.2008.092767","volume":"68","author":"PJ Mease","year":"2009","unstructured":"Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT). Ann Rheum Dis. 2009;68(5):702\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"813_CR18","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.3899\/jrheum.140056","volume":"41","author":"IH Song","year":"2014","unstructured":"Song IH, Hermann KG, Haibel H, et al. Consistently good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial. J Rheumatol. 2014;41(10):2034\u201340.","journal-title":"J Rheumatol"},{"issue":"1","key":"813_CR19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landew\u00e9","year":"2014","unstructured":"Landew\u00e9 R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014;73(1):39\u201347.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"813_CR20","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72(6):815\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"813_CR21","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706\u201319.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"813_CR22","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465\u201379.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"813_CR23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19\u201334.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"813_CR24","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41584-023-01034-z","volume":"19","author":"W Bautista-Molano","year":"2023","unstructured":"Bautista-Molano W, Fern\u00e1ndez-\u00c1vila DG, Brance ML, et al. Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis. Nat Rev Rheumatol. 2023;19(11):724\u201337.","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"813_CR25","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599\u2013613.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"813_CR26","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/annrheumdis-2021-220263","volume":"80","author":"JS Smolen","year":"2021","unstructured":"Smolen JS, Siebert S, Korotaeva TV, et al. Effectiveness of IL-12\/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. Ann Rheum Dis. 2021;80(11):1419\u201328.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"813_CR27","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1136\/annrheumdis-2019-215427","volume":"78","author":"LM \u00d8rnbjerg","year":"2019","unstructured":"\u00d8rnbjerg LM, Brahe CH, Askling J, et al. Treatment response and drug retention rates in 24 195 biologic-na\u00efve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. Ann Rheum Dis. 2019;78(11):1536\u201344.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"813_CR28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69(1):48\u201353.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"813_CR29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3899\/jrheum.180249","volume":"46","author":"LC Coates","year":"2019","unstructured":"Coates LC, Gottlieb AB, Merola JF, et al. Comparison of different remission and low disease definitions in psoriatic arthritis and evaluation of their prognostic value. J Rheumatol. 2019;46(2):160\u20135.","journal-title":"J Rheumatol"},{"issue":"5","key":"813_CR30","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","volume":"75","author":"MM Schoels","year":"2016","unstructured":"Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75(5):811\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"813_CR31","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.semarthrit.2018.05.010","volume":"48","author":"P Mease","year":"2018","unstructured":"Mease P, Strand V, Gladman D. Functional impairment measurement in psoriatic arthritis: importance and challenges. Semin Arthritis Rheum. 2018;48(3):436\u201348.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"813_CR32","volume":"8","author":"X Baraliakos","year":"2024","unstructured":"Baraliakos X, Gladman DD, Chakravarty SD, et al. BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies. Rheumatol Adv Pract. 2024;8(2):rkae058.","journal-title":"Rheumatol Adv Pract"},{"issue":"12","key":"813_CR33","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286\u201391.","journal-title":"J Rheumatol"},{"key":"813_CR34","volume":"9","author":"YH Chen","year":"2022","unstructured":"Chen YH, Huang WN, Chen YM, et al. The BASDAI cut-off for disease activity corresponding to the ASDAS scores in a Taiwanese cohort of ankylosing spondylitis. Front Med (Lausanne). 2022;9:856654.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"813_CR35","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"813_CR36","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","volume":"77","author":"PM Machado","year":"2018","unstructured":"Machado PM, Landew\u00e9 R, Heijde DV. Ankylosing spondylitis disease activity score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis. 2018;77(10):1539\u201340.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"813_CR37","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40744-019-0165-3","volume":"6","author":"P Mease","year":"2019","unstructured":"Mease P, Walsh JA, Baraliakos X, et al. Translating improvements with ixekizumab in clinical trial outcomes into clinical practice: ASAS40, pain, fatigue, and sleep in ankylosing spondylitis. Rheumatol Ther. 2019;6(3):435\u201350.","journal-title":"Rheumatol Ther"},{"issue":"9","key":"813_CR38","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/annrheumdis-2017-212076","volume":"77","author":"U Kiltz","year":"2018","unstructured":"Kiltz U, van der Heijde D, Boonen A, et al. Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. Ann Rheum Dis. 2018;77(9):1311\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"813_CR39","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21(12):2281\u20135.","journal-title":"J Rheumatol"},{"key":"813_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-004040","author":"V Navarro-Comp\u00e1n","year":"2024","unstructured":"Navarro-Comp\u00e1n V, Ramiro S, Deodhar A, et al. Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. RMD Open. 2024. https:\/\/doi.org\/10.1136\/rmdopen-2023-004040.","journal-title":"RMD Open"},{"issue":"1","key":"813_CR41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13075-024-03282-0","volume":"26","author":"L Gossec","year":"2024","unstructured":"Gossec L, Humphries B, Rutherford M, et al. Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis. Arthritis Res Ther. 2024;26(1):50.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"813_CR42","first-page":"122","volume":"25","author":"J Kaine","year":"2019","unstructured":"Kaine J, Song X, Kim G, Hur P, Palmer JB. Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using U.S. administrative claims data. J Manag Care Spec Pharm. 2019;25(1):122\u201332.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"813_CR43","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/rheumatology\/key286","volume":"58","author":"R Charlton","year":"2019","unstructured":"Charlton R, Green A, Shaddick G, et al. Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study. Rheumatology (Oxford). 2019;58(1):144\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"813_CR44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","volume":"74","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74(2):326\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"813_CR45","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.reuma.2022.04.001","volume":"19","author":"AS Bhagavathula","year":"2023","unstructured":"Bhagavathula AS, Bentley BL, Woolf B, Dissanayaka TD, Rahmani J. Increased risk of stroke among patients with ankylosing spondylitis: a systematic review and meta-analysis. Reumatol Clin. 2023;19(3):136\u201342.","journal-title":"Reumatol Clin"},{"issue":"18","key":"813_CR46","volume":"95","author":"YM Hung","year":"2016","unstructured":"Hung YM, Chang WP, Wei JC, Chou P, Wang PY. Midlife ankylosing spondylitis increases the risk of cardiovascular diseases in males 5 years later: a national population-based study. Medicine (Baltimore). 2016;95(18):e3596.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"813_CR47","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/annrheumdis-2016-209315","volume":"76","author":"JK Eriksson","year":"2017","unstructured":"Eriksson JK, Jacobsson L, Bengtsson K, Askling J. Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? Ann Rheum Dis. 2017;76(2):364\u201370.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"813_CR48","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1002\/art.30581","volume":"63","author":"SM Szabo","year":"2011","unstructured":"Szabo SM, Levy AR, Rao SR, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum. 2011;63(11):3294\u2013304.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"813_CR49","first-page":"187","volume":"10","author":"MJ Bergman","year":"2023","unstructured":"Bergman MJ, Zueger P, Patel J, et al. Clinical and economic benefit of achieving disease control in psoriatic arthritis and ankylosing spondylitis: a retrospective analysis from the OM1 registry. Rheumatol Ther. 2023;10(1):187\u201399.","journal-title":"Rheumatol Ther"},{"key":"813_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25527","author":"A Allenzara","year":"2025","unstructured":"Allenzara A, Bush K, Husni ME, et al. Diverse treatment goals in psoriatic arthritis: insights from participants in the PARC cohort. Arthritis Care Res (Hoboken). 2025. https:\/\/doi.org\/10.1002\/acr.25527.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"813_CR51","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.3899\/jrheum.151491","volume":"43","author":"S Brikman","year":"2016","unstructured":"Brikman S, Furer V, Wollman J, et al. The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: a cross-sectional study. J Rheumatol. 2016;43(9):1749\u201354.","journal-title":"J Rheumatol"},{"issue":"2","key":"813_CR52","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/1756-185X.13987","volume":"24","author":"NA Elsawy","year":"2021","unstructured":"Elsawy NA, Helal AH, Abd ElHamid HA, Abdel-Fattah YH. Fibromyalgia in patients with psoriatic arthritis: impact on disease activity indices, fatigue and health-related quality of life. Int J Rheum Dis. 2021;24(2):189\u201396.","journal-title":"Int J Rheum Dis"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00813-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00813-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00813-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:06:06Z","timestamp":1773770766000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00813-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["813"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00813-2","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Philip Mease has received research support, consulting fees, and\/or speaker bureau support from AbbVie, Acelyrin, Amgen, BMS, Century, Cullinan, Lilly, Inmagene, Johnson & Johnson, Moonlake Pharma, Novartis, Pfizer, Spyre, Sun, UCB, and Takeda. Xiaolan Ye, Christopher D Saffore, Bhumik Parikh, and Sandra Ciecinski are employees of AbbVie and may own stock or stock options. Taylor Blachley is an employee and stockholder of Thermo Fisher Scientific, Inc. This study was a collaborative effort between PPD clinical research business of Thermo Fisher and AbbVie with financial support provided by AbbVie. Melissa Eliot and Nicole Middaugh are employees of Thermo Fisher. CorEvitas Clinical Registries are supported through contracted subscriptions with multiple pharmaceutical companies. This study was a collaborative effort between PPD clinical research business of Thermo Fisher and AbbVie with financial support provided by AbbVie. Alexis Ogdie is a consultant for AbbVie, Amgen, BMS, Celgene, the PPD clinical research business of Thermo Fisher, Gilead, GSK, Janssen, Lilly, Novartis, Takeda, TREG, Pfizer, and UCB; and received grants and\/or research support from AbbVie (to University of Pennsylvania), Amgen (to Forward), BMS (to Forward), Forward\/National Databank for Rheumatic Diseases, Janssen (to University of Pennsylvania), NIH\/NIAMS, Novartis (to University of Pennsylvania), and Pfizer (to University of Pennsylvania).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practice. All participating investigators were required to obtain full board approval for conducting noninterventional research involving human patients with a limited dataset. Sponsor approval and continuing review were obtained through a central Institutional Review Board (IRB), the New England Independent Review Board (NEIRB; no. 120160610). For academic investigative sites that did not receive authorization to use the central IRB, full board approval was obtained from their respective governing IRBs, and documentation of approval was submitted to the PPD\u2122 clinical research business of Thermo Fisher Scientific (Waltham, MA, USA)  before the site\u2019s participation and initiation of any study procedures. All patients enrolled in the PPD\u2122 CorEvitas\u2122 PsA\/SpA Registry were required to provide written informed consent and authorization before participating in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}